Fedratinib: First Approval

被引：79
作者：
Blair, Hannah A. [1 ]
机构：
[1] Springer Nat, Private Bag 65901, Auckland 0754, New Zealand
来源：
DRUGS | 2019年 / 79卷 / 15期
关键词：
INHIBITOR FEDRATINIB; JAK2-SELECTIVE INHIBITOR; JAK2; INHIBITOR; THIAMINE UPTAKE; SAR302503; TG101348; MYELOFIBROSIS; TOLERABILITY; RUXOLITINIB; MECHANISM;
D O I：
10.1007/s40265-019-01205-x
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Fedratinib (INREBIC (R)) is a JAK2-selective inhibitor that has been developed as an oral treatment for myelofibrosis. In August 2019, fedratinib received its first global approval in the USA for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis. Phase III clinical development for myelofibrosis is ongoing worldwide. This article summarizes the milestones in the development of fedratinib leading to this first approval for myelofibrosis.
引用
收藏
页码：1719 / 1725
页数：7
相关论文
共 25 条
  • [1] Celgene Corporation, 2019, INREBIC FEDR CAPS OR
  • [2] Gotlib J, 2012, HAEMATOLOGICA S1, V97, P361
  • [3] SAR302503: A Jak2 inhibitor with antitumor activity in solid tumor models
    Greco, Rita
    Hurley, Raelene
    Sun, Fangxian
    Yang, Lu
    Yu, Qunyan
    Williams, Juliet
    Dorsch, Marion
    Cohen, Pamela
    Adrian, Francisco
    [J]. CANCER RESEARCH, 2012, 72
  • [4] Harrison C., 2019, HEMASPHERE, V3, P671, DOI [10.1097/01.HS9.0000564100.83392.c9, DOI 10.1097/01.HS9.0000564100.83392.C9]
  • [5] Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
    Harrison, Claire N.
    Schaap, Nicolaas
    Vannucchi, Alessandro M.
    Kiladjian, Jean-Jacques
    Tiu, Ramon V.
    Zachee, Pierre
    Jourdan, Eric
    Winton, Elliott
    Silver, Richard T.
    Schouten, Harry C.
    Passamonti, Francesco
    Zweegman, Sonja
    Talpaz, Moshe
    Lager, Joanne
    Shun, Zhenming
    Mesa, Ruben A.
    [J]. LANCET HAEMATOLOGY, 2017, 4 (07): : E317 - E324
  • [6] HOOD J, 2008, J CLIN ONCOL S, V26, P7083, DOI DOI 10.1200/jco.2008.26.15_suppl.7083
  • [7] Hood J, 2017, BLOOD, V130
  • [8] Effect of treatment with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with myelofibrosis
    Jamieson, Catriona
    Hasserjian, Robert
    Gotlib, Jason
    Cortes, Jorge
    Stone, Richard
    Talpaz, Moshe
    Thiele, Juergen
    Rodig, Scott
    Pozdnyakova, Olga
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2015, 13
  • [9] JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells
    Keohane, Clodagh
    Kordasti, Shahram
    Seidl, Thomas
    Abellan, Pilar Perez
    Thomas, Nicholas S. B.
    Harrison, Claire N.
    McLornan, Donal P.
    Mufti, Ghulam J.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (01) : 60 - 73
  • [10] Kittur J, 2008, BLOOD, V112, P969
123